Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

Bibliography

• Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;9(1):1-40
   Google Scholar
• Hortobagyi GN. Developments in chemotherapy of breast cancer. Cancer 2000;88(12 Suppl):3073-9
   PubMedGoogle Scholar
• Akritopoulou-Zanze I, Hajduk P. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 2009;14(5-6):291-7
   PubMed Web of Science ®Google Scholar
• Grimminger F, Schermuly R, Ghofrani H. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9(12):956-70
   PubMed Web of Science ®Google Scholar
• Buschbeck M. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R D 2006;7(2):73-86
   PubMedGoogle Scholar
• Manning G, Whyte DB, Martinez R, The protein kinase complement of the human genome. Science 2002;298(5600):1912-34
   PubMed Web of Science ®Google Scholar
• Rabiller M, Getlik M, Kluter S, Proteus in the world of proteins: Conformational changes in protein kinases. Arch Pharm (Weinheim) 2010;343(4):193-206
   PubMed Web of Science ®Google Scholar
• Morphy R. Selectively nonselective kinase inhibition: Striking the right balance. J Med Chem 2010;53(4):1413-37
   PubMed Web of Science ®Google Scholar
• Hasinoff B, Patel D. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 2010;10(1):1-8
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1(4):309-15
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010;69(Suppl 1):i48-51
   PubMed Web of Science ®Google Scholar
• Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein GS. "Go upstream, young man": Lessons learned from the p38 saga. Ann Rheum Dis 2010;69:i77-82
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-56
   PubMed Web of Science ®Google Scholar
• Hewitson T. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 2009;296(6):F1239-44
   PubMed Web of Science ®Google Scholar
• Stegmeier F, Warmuth M, Sellers WR, Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 2010;87(5):543-52
   PubMed Web of Science ®Google Scholar
• Hartmann J, Haap M, Kopp HG, Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10(5):470-81
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12(8):908-16
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7(5):332-44
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25(1):7-22
   PubMed Web of Science ®Google Scholar
• Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008;18:73-9
   PubMed Web of Science ®Google Scholar
• Balabanov S, Gontarewicz A, Keller G, Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011;6(4):e19164
   PubMedGoogle Scholar
• Dohse M, Scharenberg C, Shukla S, Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38(8):1371-80
   PubMed Web of Science ®Google Scholar
• Brozik A, Hegedus C, Erdei Z, Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011;7(5):623-42
   PubMed Web of Science ®Google Scholar
• Gotink K, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis 2010;13(1):1-14
   PubMed Web of Science ®Google Scholar
• Schuppan D, Afdhal N. Liver cirrhosis. Lancet 2008;371(9615):838-51
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88(1):125-72
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134(6):1655-69
   PubMed Web of Science ®Google Scholar
• de Bleser P, Jannes P, van Buul-Offers SC, Insulinlike growth factor-II/Mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transfroming growth factor-ß in cocultures with sinusoidal endothelial cells. Hepatology 1995;21:1429-37
   PubMed Web of Science ®Google Scholar
• Beljaars L, Olinga P, Molema G, Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA). Liver 2001;21:320-8
   PubMedGoogle Scholar
• Greupink R, Bakker HI, van Goor H, Mannose-6-phosphate/insulin-like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharm Res 2006;23(8):1827-34
   PubMed Web of Science ®Google Scholar
• Beljaars L, Molema G, Weert B, Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29(5):1486-93
   PubMed Web of Science ®Google Scholar
• Gonzalo T, Talman EG, van de Ven A, Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Control Release 2006;111(1-2):193-203
   PubMed Web of Science ®Google Scholar
• Moreno M, Gonzalo T, Kok RJ, Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51(3):942-52
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Noguchi R, Kuriyama S, Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2004;288:G907-13
   PubMed Web of Science ®Google Scholar
• Neef M, Ledermann M, Saegesser H, Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006;44(1):167-75
   PubMed Web of Science ®Google Scholar
• Gonzalo T, Beljaars L, van de Bovenkamp M, Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 2007;321(3):856-65
   PubMed Web of Science ®Google Scholar
• Fukushima M, Nakamuta M, Kohjima M, Fasudil hydrochloride hydrate, a rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int 2005;25(4):829-38
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Nakamuta M, Tada S, A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 2000;32(5):762-70
   PubMed Web of Science ®Google Scholar
• Mizunuma K, Ohdan H, Fudaba Y, ROCK inhibitor, Y-27632, inhibits anoxia-reoxygenation-induced contraction of hepatic stellate cells. Transplant Proc 2003;35(1):111-13
   PubMed Web of Science ®Google Scholar
• Murata T, Arii S, Mori A, Therapeutic significance of Y-27632, a rho-kinase inhibitor, on the established liver fibrosis. J Surg Res 2003;114(1):64-71
   PubMed Web of Science ®Google Scholar
• Murata T, Arii S, Nakamura T, Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 2001;35(4):474-81
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Melton AC, Santiskulvong C, Rho and p38 MAP kinase signaling pathways mediate LPA-stimulated hepatic myofibroblast migration. J Biomed Sci 2003;10(3):352-8
   PubMed Web of Science ®Google Scholar
• Tada S, Iwamoto H, Nakamuta M, A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol 2001;34(4):529-36
   PubMed Web of Science ®Google Scholar
• Hennenberg M, Biecker E, Trebicka J, Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130(3):838-54
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hennenberg M, Trebicka J, Intrahepatic upregulation of RhoA and rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55(9):1296-305
   PubMed Web of Science ®Google Scholar
• Hennenberg M, Trebicka J, Biecker E, Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007;45(2):495-506
   PubMed Web of Science ®Google Scholar
• van Beuge MM, Prakash J, Lacombe M, Reduction of fibrogenesis by selective delivery of a rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther 2011;337(3):628-35
   PubMed Web of Science ®Google Scholar
• van Beuge MM, Prakash J, Lacombe M, Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the rho-kinase inhibitor Y27632. Pharm Res 2011;28(8):2045-54
   PubMed Web of Science ®Google Scholar
• Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365(9456):331-40
   PubMed Web of Science ®Google Scholar
• Dolman MEM, Harmsen S, Storm G, Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010;62(14):1344-57
   PubMed Web of Science ®Google Scholar
• Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010;6(11):643-56
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21(11):1819-34
   PubMed Web of Science ®Google Scholar
• Haas M, Moolenaar F, Meijer DK, Specific drug delivery to the kidney. Cardiovasc Drugs Ther 2002;16(6):489-96
   PubMed Web of Science ®Google Scholar
• de Borst MH, Wassef L, Kelly DJ, Mitogen activated protein kinase signaling in the kidney: target for intervention? Signal Transduct 2005;5:1-22
   Google Scholar
• Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2(9):717-26
   PubMed Web of Science ®Google Scholar
• Prakash J, Sandovici M, Saluja V, Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp Ther 2006;319(1):8-19
   PubMed Web of Science ®Google Scholar
• Temming K, Fretz MM, Kok RJ. Organ and cell-type specific delivery of kinase inhibitors: A novel approach in the development of targeted drugs. Curr Mol Pharmacol 2008;1(1):1-12
   PubMedGoogle Scholar
• Li MO, Wan YY, Sanjabi S, Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146
   PubMed Web of Science ®Google Scholar
• Fretz M, Dolman MEM, Lacombe M, Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. J Control Release 2008;132(3):200-7
   PubMed Web of Science ®Google Scholar
• Prakash J, de Borst MH, van Loenen-Weemaes AM, Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res 2008;25(10):2427-39
   PubMed Web of Science ®Google Scholar
• Prakash J, de Borst MH, Lacombe M, Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 2008;19:2086-97
   PubMed Web of Science ®Google Scholar
• Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009;78(6):539-52
   PubMed Web of Science ®Google Scholar
• Schraa AJ, Everts M, Kok RJ, Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. Biotechnol Annu Rev 2002;8:133-65
   PubMedGoogle Scholar
• Temming K, Lacombe M, van der Hoeven P, Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjug Chem 2006;17(5):1246-55
   PubMed Web of Science ®Google Scholar
• Fitzgibbon GM, Kafka HP, Leach AJ, Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28(3):616-26
   PubMed Web of Science ®Google Scholar
• Myllarniemi M, Frosen J, Calderon Ramirez LG, Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther 1999;13(2):159-68
   PubMed Web of Science ®Google Scholar
• Kimura S, Egashira K, Nakano K, Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008;118:S65-70
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7(11):653-64
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Garlich J, De P, Dey N, A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008;68(1):206-15
   PubMed Web of Science ®Google Scholar
• Skidan I, Miao B, Thekkedath R, In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 2009;16(1):45-51
   PubMed Web of Science ®Google Scholar
• Harfouche R, Basu S, Soni S, Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009;12:325-38
   PubMed Web of Science ®Google Scholar
• Basu S, Harfouche R, Soni S, Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA 2009;106(19):7957-61
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3(1):11-22
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Robinson R, Bertram J, Reiter J, New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres. J Microencapsul 2010;27(3):263-71
   PubMed Web of Science ®Google Scholar
• Larsen AK, Ouaret D, El Ouadrani K, Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011;131(1):80-90
   PubMed Web of Science ®Google Scholar
• Gild ML, Bullock M, Robinson BG, Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7(10):617-24
   PubMed Web of Science ®Google Scholar
• Medina OP, Pillarsetty N, Glekas A, Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release 2011;149(3):292-8
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R, Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296(5577):2404-7
   PubMed Web of Science ®Google Scholar
• Temming K, Lacombe M, Schaapveld RQ, Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. ChemMedChem 2006;1(11):1200-3
   PubMed Web of Science ®Google Scholar
• Katanasaka Y, Ida T, Asai T, Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int J Pharm 2008;360(1-2):219-24
   PubMedGoogle Scholar